Lohocla Research

Lohocla Research is a private, preclinical-stage biotech targeting chronic pain and addiction through a novel multi-target therapeutic platform. Founded by renowned alcohol and addiction researcher Dr. Boris Tabakoff, the company leverages deep neuroscience expertise to design molecules that address the complex, multi-system nature of these disorders. While still pre-revenue, its approach aims to improve efficacy and safety over single-target drugs in large, underserved patient markets. Key risks include typical preclinical development challenges and future capital needs.

Multi-target small molecule drug design platform focused on creating single molecules that simultaneously modulate several dysregulated neural systems involved in chronic pain and addiction.

Lohocla competes in crowded fields with large pharma and other biotechs developing novel analgesics (e.g., NGF inhibitors, NaV blockers) and addiction treatments. Its differentiation lies in its novel multi-target pharmacology approach, which aims to address the systemic nature of these disorders more comprehensively than single-target agents.